Immunocore Holdings plc (IMCR)
| Market Cap | 1.63B |
| Revenue (ttm) | 400.02M |
| Net Income (ttm) | -35.51M |
| Shares Out | 50.70M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,430 |
| Open | 31.60 |
| Previous Close | 32.30 |
| Day's Range | 31.56 - 32.57 |
| 52-Week Range | 23.15 - 40.72 |
| Beta | 0.78 |
| Analysts | Buy |
| Price Target | 64.70 (+100.62%) |
| Earnings Date | Feb 25, 2026 |
About IMCR
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ... [Read more]
Financial Performance
In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price target is $64.7, which is an increase of 100.62% from the latest price.
News
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update
Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; ...
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025
Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md.
Immunocore announces R&D leadership evolution
Immunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice ...
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference
Immunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US communit...
Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore: Continuing To Improve The Bottom Line, But Needing A Big Catalyst
Immunocore still relies exclusively on sales of tebentafusp to fund operations. While these sales have supported the company, they have not been enough to achieve profitability. Current market sentime...
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver Meeting
Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA...
Immunocore reports third quarter financial results and provides a business update
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM...
Immunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Immunocore Holdings plc (NASDAQ:IMCR) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:50 PM EDT Company Participants Travis Coy - CFO, Executive VP & Head of Corporate De...
Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants & - Corporate Participant Bahija Jallal - CEO & Executive Director Clayton Robert...
Immunocore reports second quarter financial results and provides a business update
KIMMTRAK ® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions
RIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel ther...
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md.
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Pha...
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point
Immunocore Holdings focuses on immunotherapy for oncology, with tebentafusp approved for metastatic uveal melanoma and brenetafusp in advanced trials. IMCR's strong balance sheet, with over $800 milli...
Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript
Immunocore Holdings plc (NASDAQ:IMCR) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ET Company Participants Clayton Robertson - Head, IR Bahija Jallal - CEO Travis Coy - CFO and Head, Co...
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development